| Basics |
Myriad Genetics, Inc.
Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.
|
| IPO Date: |
October 6, 1995 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$660.89M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.50 | 1.91%
|
| Avg Daily Range (30 D): |
$0.19 | 2.65%
|
| Avg Daily Range (90 D): |
$0.19 | 2.75%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.84M |
| Avg Daily Volume (30 D): |
.91M |
| Avg Daily Volume (90 D): |
1.22M |
| Trade Size |
| Avg Trade Size (Sh.): |
121 |
| Avg Trade Size (Sh.) (30 D): |
66 |
| Avg Trade Size (Sh.) (90 D): |
82 |
| Institutional Trades |
| Total Inst.Trades: |
11,726 |
| Avg Inst. Trade: |
$1.85M |
| Avg Inst. Trade (30 D): |
$1.45M |
| Avg Inst. Trade (90 D): |
$1.47M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.49M |
| Avg Closing Trade (30 D): |
$1.33M |
| Avg Closing Trade (90 D): |
$1.43M |
| Avg Closing Volume: |
108.57K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-4.35
|
$-.29
|
$-3.57
|
|
Diluted EPS
|
$-4.35
|
$-.29
|
$-3.57
|
|
Revenue
|
$ 825.3M
|
$ 205.7M
|
$ 213.1M
|
|
Gross Profit
|
$ 580.7M
|
$ 143.8M
|
$ 151.8M
|
|
Net Income / Loss
|
$ -400.5M
|
$ -27.4M
|
$ -330.5M
|
|
Operating Income / Loss
|
$ -420.5M
|
$ -23.3M
|
$ -329.2M
|
|
Cost of Revenue
|
$ 244.6M
|
$ 61.9M
|
$ 61.3M
|
|
Net Cash Flow
|
$ 45M
|
$ 71.1M
|
$ -17.3M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Mar 26, 2009:
2:1
|
|
Sep 12, 2000:
2:1
|
|
|
|
